Abstract
Trovafloxacin, a fluoronaphthyridone derivative related to fluoroquinolones, has significant activity against gram-negative and gram-positive pathogens, including penicillin-resistantStreptococcus pneumoniae, anaerobes and atypical organisms, good tissue penetration and a long elimination half-life. Following oral administration, less than 10% of the dose is renally eliminated as unchanged drug. Hepatobiliary elimination of trovafloxacin was examined by comparing the time course and bile and serum concentrations of trovafloxacin and its metabolites following oral administration to three patients with in-dwelling nasobiliary catheters or T-tubes. Following a single 200 mg oral dose, the mean maximum plasma trovafloxacin concentration was 2.0±0.4mg/l, the area under the concentration-time curve 22.0±5.5 mg·h/l and the elimination half-life 8.5 h. Values in bile for the same subjects were 27.8±9.6 mg/l, 327.7±142.9 mg·h/l and 10.7 h. Corresponding values for the N-acetyl metabolite in bile were 3.8±3.4 mg/l, 35.3±29.8 mg·h/l and 8.3 h. The mean bile : serum ratio of trovafloxacin was 14∶9 and consistent with biliary elimination. Serum concentrations of trovafloxacin in this study were similar to those reported in healthy volunteers. Bile concentrations of trovafloxacin substantially exceeded those of theN-acetyl metabolite, suggesting efficient clearance of the metabolite or that hepatic metabolism of trovafloxacin is not extensive.
Similar content being viewed by others
References
Hendershot EF: Fluoroquinolones. Infectious Disease Clinics of North America (1995) 9:715–730
Just PM: Overview of the fluoroquinolone antibiotics. Pharmacotherapy (1993) 13, Supplement 2:4–17
von Rosenstiel N, Adam D: Quinolone antibacterials: an update of their pharmacology and therapeutic use. Drugs (1994)47:873–901
Hooper DC, Wolfson JS: Fluoroquinolone antimicrobial agents. New England Journal of Medicine (1991) 324:384–394
Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349–353
Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy (1994) 38:2471–2476
Klugman K, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistantStreptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873–874
Teng R, Harris SC, Nix DE, Schentag JJ, Foulds G, Liston TE: Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Journal of Antimicrobial Chemotherapy (1995) 36:385–394
Teng R, Tensfeldt TG, Liston TE, Foulds G: Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed-phase high-performance liquid chromatography. Journal of Chromatography. B, Biomedical Applications (1996) 675:53–59
Dalvie DK, Khosla N, Vincent J: Excretion and metabolism of trovafloxacin in humans. Drug Metabolism and Disposition (1997) 25:423–427
Wise R, Mortiboy D, Child J, Andrews JM: Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP99,219). Antimicrobial Agents and Chemotherapy (1996) 40:47–49
Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW: Determinants of non-compliance with short-term antibiotic regimens. British Medical Journal (1987) 295:814–818
Davey P, Parker S: Cost-effectiveness of once-daily oral antimicrobial therapy. Journal of Clinical Pharmacology (1992) 32:706–710
Teng R, Girard D, Gootz TD, Foulds G, Liston TE: Pharmacokinetics of trovafloxacin (CP-99,219), a new quinolone, in rats, dogs, and monkeys. Antimicrobial Agents and Chemotherapy (1996) 40:561–566
Nicolle LE: Urinary tract infection in the elderly. Journal of Antimicrobial Chemotherapy (1994) 33, Supplement A: 99–109
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melnik, G., Schwesinger, W.H., Teng, R. et al. Hepatobiliary elimination of trovafloxacin and metabolites following single oral doses in healthy volunteers. Eur. J. Clin. Microbiol. Infect. Dis. 17, 424–426 (1998). https://doi.org/10.1007/BF01691576
Issue Date:
DOI: https://doi.org/10.1007/BF01691576